IONIS PHARMACEUTICALS INC
NASDAQ: IONS (Ionis Pharmaceuticals, Inc.)
Kemas kini terakhir: 7 jam lalu75.71
-0.31 (-0.41%)
| Penutupan Terdahulu | 76.02 |
| Buka | 76.45 |
| Jumlah Dagangan | 1,654,560 |
| Purata Dagangan (3B) | 2,085,267 |
| Modal Pasaran | 12,512,028,672 |
| Harga / Pendapatan (P/E Ke hadapan) | 90.91 |
| Harga / Jualan (P/S) | 11.41 |
| Harga / Buku (P/B) | 25.14 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 5 Aug 2026 |
| Margin Keuntungan | -63.86% |
| Margin Operasi (TTM) | -111.59% |
| EPS Cair (TTM) | -2.99 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 413.80% |
| Nisbah Semasa (MRQ) | 9.66 |
| Aliran Tunai Operasi (OCF TTM) | -501.78 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -368.16 M |
| Pulangan Atas Aset (ROA TTM) | -10.59% |
| Pulangan Atas Ekuiti (ROE TTM) | -118.62% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Ionis Pharmaceuticals, Inc. | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 4.0 |
| Aktiviti Orang Dalam | -4.0 |
| Volatiliti Harga | 2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | 3.0 |
| Purata | 1.00 |
|
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 0.83% |
| % Dimiliki oleh Institusi | 108.17% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Bellevue Group Ag | 31 Dec 2025 | 4,802,199 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 104.00 (Leerink Partners, 37.37%) | Beli |
| Median | 101.50 (34.06%) | |
| Rendah | 77.00 (Stifel, 1.70%) | Pegang |
| Purata | 96.00 (26.80%) | |
| Jumlah | 3 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 80.25 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Leerink Partners | 03 Mar 2026 | 104.00 (37.37%) | Beli | 78.66 |
| Piper Sandler | 27 Feb 2026 | 100.00 (32.08%) | Beli | 81.15 |
| Needham | 26 Feb 2026 | 103.00 (36.05%) | Beli | 80.60 |
| Stifel | 26 Feb 2026 | 77.00 (1.70%) | Pegang | 80.60 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BAROLDI JOSEPH | - | 71.78 | -1,626 | -116,714 |
| KLEIN JOSEPH III | - | 75.28 | -10,111 | -761,156 |
| Jumlah Keseluruhan Kuantiti Bersih | -11,737 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -877,870 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 73.53 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| KLEIN JOSEPH III | Pengarah | 01 May 2026 | Jual automatik (-) | 10,111 | 75.28 | 761,156 |
| KLEIN JOSEPH III | Pengarah | 01 May 2026 | Pelaksanaan pilihan | 10,111 | - | - |
| BAROLDI JOSEPH | Pegawai | 28 Apr 2026 | Jual automatik (-) | 1,626 | 71.78 | 116,714 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |